India’s Fortis Healthcare pulls out of amalgamation scheme with Fortis Malar, SRL

Fortis Healthcare Ltd on Wednesday withdrew the scheme of arrangement and amalgamation with its units Fortis Malar Hospitals Ltd and SRL Ltd, citing a delay in its completion.

The scheme could not be completed even after 19 months due to reasons beyond the company’s control, Fortis Healthcare said in a statement late on Wednesday.

Fortis Malar runs a superspeciality hospital in Chennai while SRL operates a chain of pathology clinics.

Given the headwinds in the sector and less-than-optimum performance of the diagnostics business during the period of delay, the scheme may not result in optimum value for shareholders, Fortis added.

The cash-strapped hospitals operator, which has become the target of a bidding war, earlier this month said it would look at a new round of bids from four local and international parties and fixed June 14 as the last day for the submission.

(Reporting by Vishal Sridhar in Bengaluru; Editing by Sunil Nair)

  • Related Posts

    Yashoda Medicity’s Medical Tourism Footprint widens with Republic of Kazakhstan on Board

    MOU signed for Patient Referrals, Tele-Consultations and Specialist Healthcare Collaboration Delhi NCR: Unveiled not long ago, Yashoda Medcity’s reputation as being best in class healthcare facility in Delhi NCR has…

    Liver enters FATal Straits in India, AIIMS Experts red flag

    In first for India, World Congress of Gastroenterology comes calling to asses GI disease burden New Delhi: As global and national burden of digestive diseases reach a critical crossroads, World…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

    Puresta launches EVERQ, AI-powered skin-health platform

    Puresta launches EVERQ, AI-powered skin-health platform

    Stem cell therapy for autism only in approved clinical trials: Centre

    Stem cell therapy for autism only in approved clinical trials: Centre